Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENSG00000290111, designated as "novel transcript, antisense to SMAP2," is annotated as an RNA gene producing a transcript that is antisense to the SMAP2 locus[1]. It does not encode a protein or act as a receptor, enzyme, transporter, or other canonical drug target. Antisense transcripts can influence the expression, processing, or stability of their sense (protein-coding) gene counterparts through mechanisms such as RNA masking, chromatin modification, or modulation of transcriptional dynamics, but specific biological functions for this transcript have not been described in available scientific literature[3][4]. There are no known drugs, disease associations, or biomarker uses for this transcript. The entry is more accurately described as a non-coding RNA gene of uncertain function, not as a classical therapeutic target or receptor. The designation "novel transcript" further suggests incomplete annotation and a lack of experimental characterization[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to SMAP2 (ENSG00000290111).